iTeos Therapeutics (ITOS) Stock Analysis

What iTeos Therapeutics does

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

Key metrics

ETFs linked to ITOS

Broad-market and Healthcare sector ETFs an investor holding iTeos Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ITOS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for iTeos Therapeutics?

iTeos Therapeutics trades under the ticker ITOS on NASDAQ.

Which exchange is ITOS listed on?

ITOS is listed on NASDAQ.

What sector does iTeos Therapeutics operate in?

iTeos Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ITOS in a portfolio?

PortView shows ITOS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.